RANCHO CORDOVA, Calif., June 12, 2017 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (NASDAQ:KOOL), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced that Dr. Xiaochun “Chris” Xu, interim chief executive officer, will present at the 2017 Marcum MicroCap Conference on Thursday, June 15, 2017, at the Grand Hyatt Hotel in New York. Dr. Xu’s presentation is scheduled to begin at 9:00 AM.
To access a live webcast of the presentation, please visit the Investors section of Cesca Therapeutics’ website, www.cescatherapeutics.com, under the Webcasts tab. An archived replay of the webcast will be available for 90 days.
About Cesca Therapeutics Inc.
Cesca is a leading regenerative medicine company that develops, commercializes and markets a range of automated technologies for cell-based therapeutics. Its device division, ThermoGenesis, provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. Cesca is also leveraging its proprietary AutoXpress® technology platform to develop autologous stem cell-based therapies that address significant unmet needs in the vascular, cardiology and orthopedic markets.
Cesca is an affiliate of the BoyaLife Group, a China-based industry research alliance encompassing top research institutions for stem cell and regenerative medicine.